NFL Biosciences lists on Euronext Growth Paris

Back

  • €5 million raised – market capitalisation of €20 million
  • 8th biotech listed on Euronext in 2021

Paris – 5 July 2021 – Euronext today congratulates NFL Biosciences, a biopharmaceutical company specialising in the research and development of botanical medicines for the treatment of dependencies and addictions, on its listing on Euronext Growth Paris (ticker code: ALNFL).

Based in Castelnau-Le-Lez, near Montpellier, France, NFL Biosciences develops botanical drug candidates for the treatment of addictions. NFL Biosciences' most advanced botanical drug candidate is a smoking cessation aid called NFL-101, a natural product extracted from standardised, nicotine-free tobacco leaves, that is protected by two patent families. NFL Biosciences is going public in order to finance its phase II/III study, that has already been approved, on smoking cessation, and to develop treatments for other addictions such as alcohol and cannabis.

NFL Biosciences was listed through the admission to trading of the 5,234,612 shares making up its equity, of which 1,315,842 new shares were issued under a Global Offering[1], after the partial exercise of the extension option.

The admission and issue price of NFL Biosciences shares was set at €3.80 per share. Market capitalisation was €20 million on the day of listing. The offering raised about €5 million altogether.

Ignacio Faus, CEO of NFL Biosciences, said: “We would like to thank all the shareholders, both institutional and individual, who have supported us in this rights issue. We will be able to strengthen our company with new staff to support the progress of the NFL-101 clinical study, and initiate the development of the NFL-201 and NFL-301 programmes for the treatment of cannabis addiction and the reduction of alcohol consumption.

NFL Biosciences

Caption: Ignacio Faus, CEO of NFL Biosciences, and Bruno Lafont, Chief Operating Officer of NFL Biosciences, rang the bell during a ceremony this morning together with Guillaume Mordelet, Euronext’s Director Listing SME-ETI South PACA & Occitany, to celebrate the Initial Public Offering of NFL Biosciences.

About NFL Biosciences NFL Biosciences is a biopharmaceutical company based in Montpellier, France, whose most advanced botanical drug candidate is an aid to stop smoking. Known as NFL-101, this natural nicotine-free product, extracted from standard tobacco leaves, is protected by two patent families. NFL Biosciences aims to offer smokers who would like to stop a safe, natural solution that is effective over the long-term, with short-term personalized administration. Alongside NFL-101, NFL Biosciences has various development projects focused on botanical drugs for the treatment of cannabis use disorder and alcoholism. Learn more at https://www.nflbiosciences.com/

 

[1] The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €5.8 trillion in market capitalisation as of end June 2022, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.